The Spike glycoprotein receptor-binding domain (RBD) of SARS-CoV-2 mediates the viral particle’s binding to the angiotensin-converting enzyme 2 (ACE2) receptor on the surface of human cells. Therefore, Spike-ACE2 interaction is a crucial determining factor for viral infectivity.A new phylogenetic group of SARS-CoV-2 (lineage B.1.1.7), which features an amino acid substitution in the Spike RBD (N501Y mutation).
According to the new research from the Department of Health of UK, based on the data of whole genome sequencing, epidemiology and modeling, the infectiousness of variant strain of SARS-CoV-2 is almost 40-70% higher than other discoverable modifification scientist recognized. Rapid response and detection is one of the vital prevention and control measure.
The kit is used for in vitro qualitative detecting the ORF1ab/N/S genes of novel coronavirus 2019-nCoV in respiratory specimens, and performing mutation typing on N501Y simultaneously.
The kit adopts the ARMS method, takes the S gene of novel coronavirus (2019-nCoV) as the target region for mutation typing, designs the specifific primers and probes for N501Y.
|Real Time PCR Kit for NovelCoronavirus 2019-nCoV andNovel Coronavirus 2019-nCoVGene Mutation (N501Y)||48T||-20℃||Analytes: Wild-type of N501Y,Mutant type of N501Y, ORF1ab,N gene and Internal control|
- Oropharyngeal Swabs
- Nasopharyngeal Swab
- Bronchoalveolar Lavage Fluid
- RT-PCR reaction buffer
- RT-PCR enzyme mix
- Wild-type positive control
- Mutated positive control
- Negative control